About this trial
The development of in vivo biomarkers sensitive to myelin disruption represents a major clinical need to be able to monitor the demyelination processes as well as the effect of remyelinating therapies in multiple sclerosis. The investigators recently proposed a technique, derived from the conventional magnetisation transfer (MT): inhomogeneous Magnetisation Transfer (ihMT). In preliminary studies, this simple-to-implement and robust technique has shown great sensitivity for evaluating the demyelination processes. The goal of the project is to evaluate the ability of ihMT to measure and describe the spontaneous demyelination and remyelination processes involved in active lesions in a population of patients with MS at the the disease onset.
Eligibility criteria
Qualifiers
Adult patient, male and female, age 18 to 45
Patient affiliated with health insurance coverage,
Patient who signed a free and informed consent after receiving detailed, understandable and honest information,
Patient with relapsing-remitting multiple sclerosis according to the McDonald 2010 criteria
Disqualifiers
Patients with the usual contraindications for MRI (pacemaker, agitation, metal shards, claustrophobia)
Patients at risk of non-compliance to the exam: basic problems with understanding, confusion, involuntary movements, poor tolerance of prolonged supine position
Patients who are unable to give their consent: problems with understanding, lack of vigilance, confusion
Woman who is pregnant and breastfeeding
Trial design
Treatments tested in this trial
- inhomogeneous Magnetisation Transfer (ihMT) sequence
- inhomogeneous Magnetisation Transfer (ihMT) sequence at 3T